Evotec SE (EVO) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 6 wire items for EVO, including 3 SEC filings, 2 earnings updates and 1 leadership change. The most recent was published Nov 5, 2026.
Financial highlights
Full financials- Revenue, FY2025
- €788.37M
- Revenue growth
- -1.1%
- Net income, FY2025
- -€103.52M
- Net margin
- -13.1%
- Free cash flow, FY2025
- -€81.72M
- Cash
- €418.52M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks25+200%
2026-05-102026-11-01
Mix1290d
- SEC Filings6(50%)
- Other3(25%)
- Earnings2(17%)
- Leadership1(8%)
Latest news
25 items- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PREvotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 GoalsFinancial performance: Q3 and nine-month Group revenue of €164.9 m and €465.0 m, respectively (Q3: €164.2 m, 9M: €477.4 m at CER); adj. Group EBITDA of -€1.6 m and -€44.3 m, respectively (Q3: -€1.7 m, 9M: -€39.1 m at CER)Robust commercial momentum: Net sales* in D&PD base business increased 24% vs. 9M 2025 accompanied by continued positive development across key commercial indicators.FY 2026 guidance reaffirmed: Expected Group revenue of €570 to €610 m (€595 to €635 m CER) and adj. Group EBITDA of -€105 to -€70 m (-€90 to -€60 m CER).2030 framework further detailed: Around €1 billion in Group revenue by 2030 with further upside potential; adjusted EBITDA margin of 20% at YE 2028 and above 20
- PREvotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026HAMBURG, Germany, Oct. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first nine months 2026 and provide a business update on Thursday, November 5, 2026. The conference call will be held in English. Webcast detailsDate: Thursday, November 5, 2026Time: 2.00 pm CET (1.00 pm GMT, 8.00 am EST)To join the audio webcast and to access the presentation slides, please register via this link.The on-demand version of the webcast will be available on our website: www.evotec.com.Conference call detailsTo join the conference call, please pre-register via this link. You will then receive a con
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PREvotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management BoardWill lead Evotec's global scientific strategy and drive differentiation across its discovery and development services, technology platforms and proprietary innovationBrings more than 25 years of global experience in pharma, biotechnology and academiaHAMBURG, Germany, Oct. 15, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced the appointment of Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board, effective November 1, 2026. Dr. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to the challenges of drug discovery and advancing pro
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PREvotec Announces Chief Scientific Officer TransitionDr. Cord Dohrmann to step down as of September 30, 2026Search ongoing for a successorHAMBURG, Germany, Sept. 29, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made by mutual consent between Dr. Dohrmann and the Company. Dr. Christian Wojczewski, Chief Executive Officer of Evotec, said:"I would like to thank Cord for his long service and many contributions to Evotec over the past 16 years. Throughout his tenure, he has played a significant role in strengthening the scientific excellence
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PRJust - Evotec Biologics Advances U.S. Department of War Antibodies Against Orthopoxvirus into Phase 1 Clinical StudiesFirst-in-human Phase 1 study initiated for investigational antibodies targeting orthopoxviruses developed under U.S. Department of War Accelerated Antibodies ProgramSupports development of countermeasures against orthopoxviruses, a high-priority biological threat family that includes viruses responsible for smallpoxDelivers integrated process development, regulatory submission and manufacturing of clinical trial material at J.POD® Redmond facilityDemonstrates scalable model for development and continuous manufacturing for biodefense preparednessSEATTLE and HAMBURG, Germany, Sept. 9, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced the initiation of
- PREvotec and Plectonic Enter Research Collaboration to Explore New Generation of T-Cell-Engaging Approaches for Solid TumorsCollaboration aims to validate Evotec's proprietary BiTco costimulatory CD2 bispecifics platform in combination with Plectonic's logic-gated DNA-protein immunotherapy technology LOGIBODY®BiTco designed to boost T cell activation by engaging a costimulatory signaling pathwayLOGIBODY® designed to enhance precision of T cell activation based on multispecific antigen signatureHAMBURG, Germany and HALLBERGMOOS, Germany, Sept. 2, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the s
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PREvotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory DiseasesCollaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's discovery-stage programsEvotec to deliver validated hit series across multiple high-value targets for large inflammatory and autoimmune diseases with high unmet medical needHAMBURG, Germany, Aug. 6, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. (NASDAQ:ODTX) to discover potential new treatments in autoimmune and inflammatory diseases. Under the agreement, Odyssey
- PRNiagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168Collaboration will support pharmacokinetic, pharmacodynamic, and bioanalytical studies for Niagen Bioscience’s lead investigational candidate for rare pediatric diseasesEvotec brings deep drug development expertise, serving leading pharmaceutical and biotechnology companies across the life sciences industryNiagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has selected Evotec (NASDAQ:EVO, Frankfurt Prime Standard: EVT)), a global life science company specializing in drug discovery and development, as a contract research organization to support the advancement of NB4168.
- PREvotec Selects Navan to Unify Global Travel, Payments, and Expense ManagementGlobal drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting Navan (NASDAQ:NAVN), the global AI-powered business travel and expense platform, today announced that Evotec (NASDAQ:EVO, Frankfurt Prime Standard: EVT)), the global drug discovery and development company, has selected Navan to manage its complete corporate Travel and Expense (T&E) program in its top global markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722261092/en/Global drug discovery leader partners with Navan to drive operational excellence and eliminate manual expense reporting A life scienc
- ANALYSTEvotec SE downgraded by BerenbergBerenberg downgraded Evotec SE from Buy to Hold
- ANALYSTEvotec SE downgraded by TD Cowen with a new price targetTD Cowen downgraded Evotec SE from Buy to Hold and set a new price target of $2.00
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PRAd hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 OutlookDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014 HAMBURG, Germany, July 13, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced preliminary unaudited financial results for the second quarter and first half of 2026 and updated its full-year 2026 outlook. Full financial results for the second quarter and first half of 2026 will be published on August 13, 2026, as scheduled.Based on preliminary figures, Evotec expects Group revenues for the first half of 2026 of approximately €300.1 million and adjusted Group EBITDA of approximately -€42.7 million. As of June 30, 2026, liquidity is expected to amount to approx
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PRJust - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for BiologicsExpands Just – Evotec Biologics partner-enablement and technology licensing model for proprietary continuous manufacturing platformEnables deployment of continuous manufacturing platform in partner-owned facilities to support higher productivity and flexibility compared with fed-batch technology biologics manufacturingModular manufacturing infrastructure, equipment and proprietary technology enable rapid and cost-efficient increase in capacity for biologics manufacturingSEATTLE and HAMBURG, Germany, June 30, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enable
- SECSEC Form 6-K filed by Evotec SE6-K - Evotec SE (0001412558) (Filer)
- PREvotec Reports Results of the Annual General Meeting 202611.06.2026 / 15:30 CET/CESTThe issuer is solely responsible for the content of this announcement. All agenda items adoptedDieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory BoardDieter Weinand appointed Chairman of the Supervisory BoardDr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory BoardHAMBURG, Germany, June 11, 2026 /PRNewswire/ -- Evotec SE (NASDAQ:EVO, Frankfurt Prime Standard: EVT)) today announced the results of its Annual General Meeting.All agenda items put to vote were adopted by the Company's shareholders with the required majority.Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board. Following the Annual Ge
- NEWSEvotec Appoints Rui Wang as Head of Global In Silico and AIHAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings to Evotec more than 20 years of experience supporting global pharma and biotech organizations to embed scalable data, analytics & AI across R&D, drug development, manufacturing and supply chain functions. In his role, Mr. Wang will spearhead the integration of computational science and data-driven decision-making across the R&D operation, with the goal of creating enterprise-scale solutions that ensure AI and in silico science become key pillars of the Evotec commercial val
- NEWSEvotec SE Successfully Placed €116.1 Million Convertible BondsNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH, OR TO PERSONS IN ANY JURISDICTION TO WHOM, SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. HAMBURG, GERMANY / ACCESS Newswire / May 12, 2026 / Evotec SE (the "Company" or "Evotec") (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) placed today senior unsecured convertible bonds due 2033, convertible into new and/or existing no-par value ordinary bearer shares of the Company (the "Shares"), in an aggregate principal amount of €116.1 million (the "Bonds"). The pre-emption rights of the shareholders were exc
EVO FAQ
11 questionsWhat does Evotec SE do?
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin...What is the latest news on EVO?
In the last 30 days Quantisnow tracked 6 wire items for EVO: 3 SEC filings, 2 earnings updates and 1 leadership change. The most recent was published on November 5, 2026.What is EVO revenue?
Evotec SE (EVO) reported €788.37M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 1.1% from the year before.Is EVO profitable?
No. Evotec SE reported a net loss of €103.52M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does EVO have?
Evotec SE reported €418.52M in cash and cash equivalents and €276.40M of debt on its most recent balance sheet in SEC filings.Where does EVO stock trade?
Evotec SE (EVO) is listed on NASDAQ.What sector and industry is EVO in?
Evotec SE operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Evotec SE go public?
Evotec SE (EVO) completed its IPO in 2021.What are analysts saying about EVO?
Across the last 8 analyst actions on Evotec SE, there was 1 upgrade and 5 downgrades. The most recent action was from Berenberg: Hold on 2026-07-16. Recent price targets range from $2.00 to $7.00.What companies are similar to EVO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EVO side-by-side with any of them on Quantisnow.How can I track EVO on Quantisnow?
Quantisnow aggregates Evotec SE's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EVO to receive live email and push alerts on every new disclosure.